by MM360 Staff | Jun 3, 2025 | Uncategorized
Source: CureToday articles Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ advanced/metastatic NSCLC. Read More
by MM360 Staff | Jun 3, 2025 | Uncategorized
Source: CureToday articles The COCOON dermatologic management regimen reduced the quality-of-life impact of Rybrevant/Lazcluze vs SOC treatment in patients with EGFR-mutated NSCLC. Read More
by MM360 Staff | Jun 3, 2025 | Uncategorized
Source: CureToday articles Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer. Read More
by MM360 Staff | Jun 3, 2025 | Uncategorized
Source: CureToday articles Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: ASCO Daily News Dr. John Sweetenham shares highlights from Day 4 of the 2025 ASCO Annual Meeting, including new research on maintenance therapy in small cell lung cancer and a virtual reality psychosocial intervention for patients undergoing hematopoietic stem...
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer. Read More
